🇺🇸 FDA
Pipeline program

Givosiran

ALN-AS1-002

Phase 2 small_molecule completed

Quick answer

Givosiran for Acute Intermittent Porphyria is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ALNYLAM PHARMACEUTICALS, INC.
Indication
Acute Intermittent Porphyria
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials